Cancer Family
Transitional Cell Neoplasm
CI-CAN-00000374Explore in graph →
Non-malignant254 active trials5 approved drugs23 evidence items
- NCIt
- C6783
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000374Explore in graph →
Clinical trials
753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT04486781 | A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma | unknown | Phase 2 | 38 | Vasgene Therapeutics, IncINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT03549715 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma(NEMIO) | unknown | Phase 1 / Phase 2 | 121 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04492293 | An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer | unknown | Phase 2 | 115 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06178601 | A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 36 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT05912205 | Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05895864 | Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 34 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05823246 | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 2 | 66 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT05775874 | A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | unknown | Phase 2 | 80 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT04730219 | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | unknown | Phase 2 | 48 | Tianjin Medical University Second HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03062059 | The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence | unknown | Phase 2 | 134 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05322187 | Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy(sPLENTY-pc) | unknown | Phase 2 / Phase 3 | 15 | RenJi HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05318339 | A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 8, 2022 | clinicaltrials |
| NCT02535650 | Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma | unknown | Phase 2 | 19 | Samsung Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05160285 | Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma | unknown | Phase 2 | 29 | YULISUOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04839510 | A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer | unknown | Phase 2 | 58 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 14, 2021 | clinicaltrials |
| NCT03219775 | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma(TITAN-TCC) | unknown | Phase 2 | 169 | AIO-Studien-gGmbHOTHER | 2 | Nov 3, 2021 | clinicaltrials |
| NCT04730232 | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable | unknown | Phase 2 | 63 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05086666 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | unknown | Phase 1 / Phase 2 | 108 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT05030077 | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | unknown | Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT03263039 | Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab(RESPONDER) | unknown | Phase 2 | 80 | Erasmus Medical CenterOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT04878250 | Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder(PEBBLE) | unknown | Phase 2 | 49 | Queen Mary University of LondonOTHER | 0 | May 7, 2021 | clinicaltrials |
| NCT04383067 | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | unknown | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04211012 | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | unknown | Phase 2 | 30 | Jun GuoOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03113266 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | unknown | Phase 2 | 370 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04264936 | A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer | unknown | Phase 1 / Phase 2 | 36 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03745911 | Paclitaxel and TAK-228 in Urothelial Carcinoma | unknown | Phase 2 | 52 | Associació per a la Recerca Oncologica, SpainOTHER | 1 | Nov 19, 2018 | clinicaltrials |
| NCT03676946 | A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma | unknown | Phase 1 / Phase 2 | 15 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT03209206 | The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence | unknown | Phase 2 | 84 | Seoul National University HospitalOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02278978 | BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma | unknown | Phase 2 | 129 | National Taiwan University HospitalOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT01487915 | Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma(COACH) | unknown | Phase 2 | 80 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01215877 | Tesetaxel for Previously Treated Patients With Bladder Cancer | unknown | Phase 2 | 33 | Genta IncorporatedINDUSTRY | 2 | Jul 11, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2024source: clinicaltrials